Coherus BioSciences Inc (CHRS)

[Mile High Marauder]

Where in the world is all the selling coming from-in this stock? Somebody really must not have liked the acquisition they did? 17%+ short?!? Management better get their act together. They’ve taken a stock from $8 to $3 in six months! $20 plus price targets? Seems like some serious BS to me and I own the stock

[eneels01]

$9 possible by 2024…

[AJ Freely]

$CHRS - 👆Up 11.7% Pre-Market/ Current Price $4.94
👉Reports Q2 '23 Financial Results and Business Highlights
👉Net revenue rose 81% from prior quarter to $58.7 million – 👉CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter

[SmokeSignals]

Hey...I went and bought a handful of calls after I got out of them last week. doing pretty good. might dump them today...freakin Jans...5's and 10 strikes..hope your OK...

[SmokeSignals]

hey..have a great holiday! let me know whats next. Is all good. Nobody can get em all right. We keep trying....stay safe

[SmokeSignals]

uh oh..i'm rootin for $3 (sorry) out of them calls

[SmokeSignals]

lol got calls and puts>puts looking sweet @ the moment, hope it goes the other way (north) lol

[stock1ace1]

10 mill short squeeze watch on fda news today $

[stock1ace1]

Chrs gapping @9$

[SmokeSignals]

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $18.60 average price target, which is a 183.97% upside from current levels.
https://ih.advfn.com/stock-market/NASDAQ/coherus-biosciences-CHRS/stock-news/89617584/coherus-biosciences-chrs-receives-a-buy-from-mizuh

[SmokeSignals]

holdin a whole bunch of calls 5's, 7 1/2's, and 10's lol with a few $5 puts to cover..lol stay warm!

[SmokeSignals]

I'm sleeping with my binoculars on.

[stock1ace1]

Pdufa date to tomorrow 12/23

[stock1ace1]

Fda news tomorrow on drug approval

[Wheat123]

98.6% Institutional ownership.

I'm looking for high institutional ownership companies that are at multi-year lows.

[Big Momma]

Big Momma thinks more to come this week.

[dinogreeves]

"We eagerly anticipate results from additional Phase 3 studies in esophageal, lung, liver, breast, kidney, bladder, stomach, and skin cancers.”

[bigrun]

ok

[dinogreeves]

YW. Just watch it premarket and then decide, if it breaks 23, then I would consider getting in, by the time Robinhood jumps in it should be over 25 and they could push this over 30 tomorrow and as you probably know, Robinhood can only get in after 6:00 AM Cali time. Good luck.

[bigrun]

Thx man

[bigrun]

thx

[dinogreeves]

Read the press release they issued today, most importantly read the indications that this science can be approached on as well. 14% short position, they have 17 days to cover. Over 400 million in revenues, this is not clinical stage biotech, this commercial stage biotech, they have close to 400 million in the books and 400 million in debt, but remember they already have revenues. They are Redwood California based company with over 200 employees, market cap as it stands a little over 1 billion, with this many indications and survival rate for lung cancer and completion of Phase 3, now they wait for FDA approval, the survival rate increases 5-6 months, sure it is not a cure, but 5-6 months is life time for cancer patients. In my personal opinion, it will do at least 50% tomorrow, possibly more, but who know. All I know at this point the news was very late in the day, I don't know if that was strategic or what, but it close at 19 and change, the press release hit the wires at 3.50 PM in Cali time, so investment community is not aware, but if they are watching this from tonight tomorrow could be a big day for this. This to me is the next MRN*A, two years time, this is sitting pretty at triple digits easy and I am talking 200-300 dollars, market cap if all indications actually work, could reach 15-20 billion by that time. Good luck.

[crudeoil24]

As of July 31, 13.87% short interest.

[crudeoil24]

Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
6:41 pm ET August 18, 2021 (Globe Newswire) Print
- Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone -

- Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC -

- Study to be presented September 13 at IASLC 2021 World Conference on Lung Cancer -

Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced positive interim results from the pivotal study "CHOICE-01" (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival (PFS) per RECIST v1.1 compared to chemotherapy alone.

The results will be summarized September 13 in an oral presentation by Professor Jie Wang, MD, PhD, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, during the Mini Oral Session at the 2021 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC). The abstract is now available on the WCLC website.

[bigrun]

What happened here after trading hours? What is up with he spike tonight? thx

[dinogreeves]

Huge move for the rest of this week and beyond. Massive indications.

[dinogreeves]

You got to love the institutions on this ticker


https://finance.yahoo.com/quote/CHRS/holders?p=CHRS

[dinogreeves]

500 million in revenues, only way is up. Give it 2 months this will be sitting at 70-80 dollars by then.


https://finance.yahoo.com/news/coherus-junshi-biosciences-announce-positive-224100183.html

[Big Momma]

Big explosion after hours here.

[dinogreeves]

This is the holy grail guys, this market cap will be in the 8-10 billion in less than 3 months. Many, many indications. Actually I would not be surprised if this hit 40 tomorrow and 50 on Friday.

[dinogreeves]

CHRS is the next big runner tomorrow, by end of the week 50-60 dollars.

[Dr Speculator Ninja]

Board is dead, eh?

[DewDiligence]

CHRS had its 4Q17 earnings release and CC yesterday and said that the FDA accepted CHRS' proposed assay to measure immunogenicity of the company's Neulasta FoB.

I'm surprised the stock is up so much today. FDA acceptance of the proposed assay is not the same as FDA acceptance of the assayed immunogenicity data, which is the issue of consequence for this program.

[crudeoil24]

Strong move up! CHRS

[DewDiligence]

Transcript of CHRS 3Q17 CC:

https://finance.yahoo.com/news/edited-transcript-chrs-earnings-conference-013547179.html

[DewDiligence]

CHRS -7% on suspension of Humira-FoB development: #msg-135992347.

[DewDiligence]

CHRS 3Q17 results:

https://globenewswire.com/news-release/2017/11/06/1175311/0/en/Coherus-BioSciences-Reports-Third-Quarter-2017-Operating-and-Financial-Results.html

[DewDiligence]

Musings on ABBV-AMGN Humira settlement:

#msg-134976468
#msg-134989206

[BottomBounce]

$CHRS Coherus Biosciences, Inc. https://www.barchart.com/story/stocks/quotes/OTIC/news/3925902/best-relative-performance-in-the-biotechnology-industry-detected-in-shares-of-coherus-bioscien-chrs-otic-tsro-imgn-alny

[DewDiligence]

USPTO denies CHRS’ IPR on ABBV’s ‘619 patent: #msg-134452711.

[DewDiligence]

CHRS raises $75M in private placement: #msg-133994513.

[DewDiligence]

CHRS 2Q17 CC transcript:

https://finance.yahoo.com/news/edited-transcript-chrs-earnings-conference-122143114.html

[DewDiligence]

CHRS now hopes to submit Humira FoB applications to both FDA and EMA in 2H18 (later than previously announced), using one of multiple formulations CHRS is still developing to work around ABBV’s formulation patents.

CHRS has found a new fill/finish CMO to handle product for both the FDA and EMA applications, addressing the issue disclosed in June (#msg-132511112).

Source: Today’s 2Q17 CC.

[DewDiligence]

…what is a success rate of approval of FOBs.

In the US, specifically, there are too few data points to give a meaningful success rate. Moreover, some FoBs, such as AMGN’s Amjevita (Humira FoB)s have been approved by the FDA but not yet launched due to litigation.

In the EU, the approval rate for FoBs has been very high; however, the EU does not have interchangeable FoBs, so FoB products must be marketed as branded drugs to garner any meaningful commercial uptake.

Do you personally think that CHRS is a good investment?

Not particularly. I prefer MNTA, which has more going on than just FoBs (see #msg-132316871).

[tika1]

Thanks Dew for pointing mistake.

Generally what is a success rate of approval of FOBs. Do you personally think that CHRS is a good investment?

[DewDiligence]

They're not generic drugs. They're follow-on biologics.

[tika1]

Coherus BioSciences is at 52 weeks low.

If both generic drugs get approval, it could be multiple bagger from here. It may go below $10 though.

[Inoviorulez]

https://seekingalpha.com/article/4085829-coherus-biosciences-prospects-arsenal

[DewDiligence]

30% workforce reduction: #msg-132546687.

[DewDiligence]

CHRS BLA for Humira FoB delayed to 1H18 due to fill/finish problems:

https://www.sec.gov/Archives/edgar/data/1512762/000119312517213200/d389037d8k.htm